Eli Lilly has launched Lormalzi, a monthly treatment for early Alzheimer’s disease, in India. The therapy targets amyloid plaques and is set to be available this month. Positioned as part of the company’s broader push in specialty medicines, Lormalzi comes with a steep price tag of ₹91,688 per vial. The move signals rising focus on Alzheimer’s innovation in India.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
